Startup gives surgeons a real-time view of breast cancer during surgery
The drug-device combination developed by MIT spinout Lumicell is poised to reduce repeat surgeries and ensure more complete tumor removal.
The drug-device combination developed by MIT spinout Lumicell is poised to reduce repeat surgeries and ensure more complete tumor removal.
MIT engineers’ new model could help researchers glean insights from genomic data and other huge datasets.
The combination of phototherapy and chemotherapy could offer a more effective way to fight aggressive tumors.
SMART researchers find mesenchymal stromal cells are an attractive alternative to current costly, time-intensive treatments.
Labs that can’t afford expensive super-resolution microscopes could use a new expansion technique to image nanoscale structures inside cells.
A research scientist and internationally recognized authority in the field of blood cell development reflects on 45 years at MIT.
MIT’s innovation and entrepreneurship system helps launch water, food, and ag startups with social and economic benefits.
MIT researchers find that the first dose primes the immune system, helping it to generate a strong response to the second dose, a week later.
MIT scientists’ discovery yields a potent immune response, could be used to develop a potential tumor vaccine.
MD/PhD student Sayo Eweje seeks to develop new technologies for delivering RNA and protein therapies directly to the body’s cells.
Bioengineer and artist David Kastner seeks to unlock the secrets of catalysis and improve science communication through eye-catching visuals.
Custom plates display expressions of scholarship, creativity, and MIT pride among Institute affiliates.
The IDEAS Social Innovation Challenge helps students hone their entrepreneurship skills to create viable ventures for public good.
A chip the size of a pack of cards uses fewer resources and a smaller footprint than existing automated manufacturing platforms and could lead to more affordable cell therapy manufacturing.
By designing new tools that can analyze huge libraries of immune cells and their targets, Michael Birnbaum hopes to generate better T cell therapies for cancer and other diseases.